ArticleRadiation oncology (London, England)2026
Bridging radiotherapy before anti-CD19 CAR T-cell therapy for Large B-cell lymphoma - results from a single-center study.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating new and "old" cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy (RT) with immunochemotherapy (ICT) followed by CAR T-cell therapy may have synergistic effects due to cytoreduction and enhancing antigen spread, thereby inducing anti-cancer immune responses. The aim of this study was to analyze retrospective comparative data on the use of RT prior to anti-CD19 directed CAR T-cell therapy with a special focus on cytoreduction and RT related side effects.
methodsAll patients aged ≥ 18 years with relapsed/ refractory Large B-Cell-lymphoma (r/r LBCL) treated with anti-CD19 CAR T-cell therapy in our institution from 05/ 2019-08/2023 were analyzed retrospectively, with the RT therapy group comprising all patients receiving RT with or without concomitant systemic therapy. The control (CO) group was manually matched on age, prior therapy lines and remission state at lymphodepletion. Post-RT tumor volumes (TV) were calculated for 6 out of 7 patients pre-CAR T and for 1 patient post-CAR T. Primary endpoints were reduction of TV and CAR T as well as RT related side effects. Secondary endpoints included overall survival (OS) and progression free survival (PFS).
results8 patients receiving RT within 60 days prior to CAR T-cell infusion and 8 controls were included in the final analysis. 6 out of 8 patients received concomitant bridging therapy. RT alone or in combination with concomitant systemic therapy led to a significant reduction of TV (average reduction of 68%) within the radiated field from baseline to post RT (p = 0.028). The combination of RT and CAR T-cell therapy was not associated with an increased rate of CAR T related side effects or complications (cytokine release syndrome p = 0.6, immune effector cell-associated neurotoxicity p = 0.2, corticosteroid use p > 0.9, Tocilizumab use p > 0.9, transfer to intensive care unit p = 0.6). OS and PFS did not differ between the RT- and CO-group (OS p = 0.64, PFS p = 0.35).
conclusionsOur data indicate that RT is a feasible and effective way of cytoreduction before CAR T-cell therapy, also in combination with systemic chemotherapy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.